Aims To examine the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …

The complex pathobiology underlying cardiovascular diseases (CVDs) has yet to be
explained. Aberrant epigenetic changes may result from alterations in enzymatic activities …

Heart failure (HF) management is challenging due to high clinical heterogeneity of this
disease which makes patients responding differently to evidence-based standard therapy …

The liver is not the exclusive site of glucose production in humans in the postabsorptive
state. Robust data support that the kidney is capable of gluconeogenesis and studies have …

Cardiac fibrosis (CF) is considered an ultimate common pathway of a wide variety of heart
diseases in response to diverse pathological and pathophysiological stimuli. Mitochondria …

Despite the current reductionist approach providing an optimal indication for diagnosis and
treatment of patients with heart failure with reduced ejection fraction (HFrEF), there are no …

Progresses in liquid-based assays may provide novel useful non-invasive indicators of
cardiovascular (CV) diseases. By analysing circulating cells or their products in blood, saliva …

The aim of this study is to explore the role of circCELF1/miR-636/DKK2 pathway in
myocardial fibrosis (MF). RT-qPCR and western blot were used to detect the expression of …

Large clinical studies conducted with sodium-glucose co-transporter 2 inhibitors (SGLT2i) in
patients with type 2 diabetes and heart failure with reduced ejection fraction have …

The lack of a precise stratification algorithm for predicting patients at high risk of graft
rejection challenges the current solid organ transplantation (SOT) clinical setting. In fact, the …